These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28615225)

  • 1. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by
    Abu Eid R; Ahmad S; Lin Y; Webb M; Berrong Z; Shrimali R; Kumai T; Ananth S; Rodriguez PC; Celis E; Janik J; Mkrtichyan M; Khleif SN
    Cancer Res; 2017 Aug; 77(15):4135-4145. PubMed ID: 28615225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
    Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
    Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy.
    Martí i Líndez AA; Dunand-Sauthier I; Conti M; Gobet F; Núñez N; Hannich JT; Riezman H; Geiger R; Piersigilli A; Hahn K; Lemeille S; Becher B; De Smedt T; Hugues S; Reith W
    JCI Insight; 2019 Nov; 4(24):. PubMed ID: 31751318
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
    Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
    Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
    J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8
    Hermans D; Gautam S; García-Cañaveras JC; Gromer D; Mitra S; Spolski R; Li P; Christensen S; Nguyen R; Lin JX; Oh J; Du N; Veenbergen S; Fioravanti J; Ebina-Shibuya R; Bleck C; Neckers LM; Rabinowitz JD; Gattinoni L; Leonard WJ
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6047-6055. PubMed ID: 32123114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
    Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
    Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation.
    Pollizzi KN; Patel CH; Sun IH; Oh MH; Waickman AT; Wen J; Delgoffe GM; Powell JD
    J Clin Invest; 2015 May; 125(5):2090-108. PubMed ID: 25893604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
    Church SE; Jensen SM; Antony PA; Restifo NP; Fox BA
    Eur J Immunol; 2014 Jan; 44(1):69-79. PubMed ID: 24114780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
    Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
    J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.
    Berezhnoy A; Castro I; Levay A; Malek TR; Gilboa E
    J Clin Invest; 2014 Jan; 124(1):188-97. PubMed ID: 24292708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2 during in vitro priming promotes subsequent engraftment and successful adoptive tumor immunotherapy by persistent memory phenotypic CD8(+) T cells.
    Bathe OF; Dalyot-Herman N; Malek TR
    J Immunol; 2001 Oct; 167(8):4511-7. PubMed ID: 11591778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.
    Díaz-Montero CM; El Naggar S; Al Khami A; El Naggar R; Montero AJ; Cole DJ; Salem ML
    Cancer Immunol Immunother; 2008 Apr; 57(4):563-72. PubMed ID: 17726606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memory T cells specific for murine cytomegalovirus re-emerge after multiple challenges and recapitulate immunity in various adoptive transfer scenarios.
    Quinn M; Turula H; Tandon M; Deslouches B; Moghbeli T; Snyder CM
    J Immunol; 2015 Feb; 194(4):1726-1736. PubMed ID: 25595792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
    Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Kammula US
    Cancer Res; 2015 Aug; 75(16):3216-26. PubMed ID: 26100671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells.
    Shimizu K; Yamasaki S; Shinga J; Sato Y; Watanabe T; Ohara O; Kuzushima K; Yagita H; Komuro Y; Asakura M; Fujii S
    Cancer Res; 2016 Jul; 76(13):3756-66. PubMed ID: 27371739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8
    Abu Eid R; Friedman KM; Mkrtichyan M; Walens A; King W; Janik J; Khleif SN
    Oncoimmunology; 2015 May; 4(5):e1005448. PubMed ID: 26155399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model.
    Contreras A; Beems MV; Tatar AJ; Sen S; Srinand P; Suresh M; Luther TK; Cho CS
    J Immunother Cancer; 2018 May; 6(1):41. PubMed ID: 29843822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
    Rolle CE; Carrio R; Malek TR
    Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Context-Dependent Role for IL-21 in Modulating the Differentiation, Distribution, and Abundance of Effector and Memory CD8 T Cell Subsets.
    Tian Y; Cox MA; Kahan SM; Ingram JT; Bakshi RK; Zajac AJ
    J Immunol; 2016 Mar; 196(5):2153-66. PubMed ID: 26826252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.